• Pomdoctor management commentary for the six months ended June 30, 2026 cited net revenue up 6% to RMB 185 million.
• Mix shifted toward internet hospital revenue, up 49.3% to RMB 100.26 million, led by online pharmacy sales growth.
• Pharmaceutical supply chain revenue fell 21% to RMB 84.74 million, driven by reduced wholesale with a large customer.
• Gross margin slipped to 13.7% from 16.2% as online pharmacy added more best-selling products with lower margins.
• Net loss widened to RMB 238.17 million, reflecting RMB 215.7 million in share-based compensation tied to marketing, administrative, R&D services.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pomdoctor Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104640), on September 29, 2026, and is solely responsible for the information contained therein.